🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "huge turning point" in the effort against superbug strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise worldwide, with figures suggesting over 82 million infections per year. Particularly high rates are reported in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary step in the context of rising global incidence, escalating drug resistance and the highly restricted treatment choices presently on offer.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The WHO has classified it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Receive Clearance

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Scientists anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which up to this point has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the existing first-line therapy, which uses two antibiotics. The research involved hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the authority to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have expressed positive views. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is deemed vital to reduce the burden of the illness for patients and to prevent the spread of extremely resistant gonorrhoea around the world.